Skip to main content

Table 2 Frequency of treatment-emergent adverse events (AEs)

From: A phase 1/2, open-label assessment of the safety, tolerability, and efficacy of transdermal cannabidiol (ZYN002) for the treatment of pediatric fragile X syndrome

All treated patients (N = 20)

Treatment-emergent adverse events

Frequency (%)

Gastroenteritis

5 (25%)

Vomiting

2 (10%)

Upper respiratory tract infection

2 (10%)

Mouth ulceration

1 (5%)

Paraesthesia oral

1 (5%)

Diarrhea

1 (5%)

Application site dryness

1 (5%)

Application site rash

1 (5%)

Influenza

1 (5%)

Viral infection

1 (5%)

Viral upper respiratory tract infection

1 (5%)

Otitis media

1 (5%)

Tonsillitis

1 (5%)

Limb injury

1 (5%)

Eosinophil count abnormal

1 (5%)

Neck pain

1 (5%)

Pain in extremity

1 (5%)

Dizziness

1 (5%)

Lethargy

1 (5%)

Psychomotor hyperactivity

1 (5%)

Enuresis

1 (5%)

Stereotypy

1 (5%)

Nightmare

1 (5%)

Pruritus

1 (5%)

Eczema

1 (5%)

Rash pruritic

1 (5%)

  1. Note. Frequency reflects all reported events; individual patients may have experienced more than one AE